Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

733 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Inhibition of the NKp44-PCNA Immune Checkpoint Using a mAb to PCNA.
Kundu K, Ghosh S, Sarkar R, Edri A, Brusilovsky M, Gershoni-Yahalom O, Yossef R, Shemesh A, Soria JC, Lazar V, Joshua BZ, Campbell KS, Elkabets M, Porgador A. Kundu K, et al. Among authors: soria jc. Cancer Immunol Res. 2019 Jul;7(7):1120-1134. doi: 10.1158/2326-6066.CIR-19-0023. Epub 2019 Jun 4. Cancer Immunol Res. 2019. PMID: 31164357 Free PMC article.
A novel epidermal growth factor receptor inhibitor promotes apoptosis in non-small cell lung cancer cells resistant to erlotinib.
de La Motte Rouge T, Galluzzi L, Olaussen KA, Zermati Y, Tasdemir E, Robert T, Ripoche H, Lazar V, Dessen P, Harper F, Pierron G, Pinna G, Araujo N, Harel-Belan A, Armand JP, Wong TW, Soria JC, Kroemer G. de La Motte Rouge T, et al. Among authors: soria jc. Cancer Res. 2007 Jul 1;67(13):6253-62. doi: 10.1158/0008-5472.CAN-07-0538. Cancer Res. 2007. PMID: 17616683
Molecular Characteristics of ERCC1-Negative versus ERCC1-Positive Tumors in Resected NSCLC.
Friboulet L, Barrios-Gonzales D, Commo F, Olaussen KA, Vagner S, Adam J, Goubar A, Dorvault N, Lazar V, Job B, Besse B, Validire P, Girard P, Lacroix L, Hasmats J, Dufour F, André F, Soria JC. Friboulet L, et al. Among authors: soria jc. Clin Cancer Res. 2011 Sep 1;17(17):5562-72. doi: 10.1158/1078-0432.CCR-11-0790. Epub 2011 Jul 12. Clin Cancer Res. 2011. PMID: 21750204
Array CGH and PIK3CA/AKT1 mutations to drive patients to specific targeted agents: a clinical experience in 108 patients with metastatic breast cancer.
Arnedos M, Scott V, Job B, De La Cruz J, Commo F, Mathieu MC, Wolp-Diniz R, Richon C, Campone M, Bachelot T, Dalenc F, Dessen P, Lacroix L, Lazar V, Soria JC, Delaloge S, Andre F. Arnedos M, et al. Among authors: soria jc. Eur J Cancer. 2012 Oct;48(15):2293-9. doi: 10.1016/j.ejca.2012.06.014. Epub 2012 Jul 26. Eur J Cancer. 2012. PMID: 22840369
Prognostic impact of vitamin B6 metabolism in lung cancer.
Galluzzi L, Vitale I, Senovilla L, Olaussen KA, Pinna G, Eisenberg T, Goubar A, Martins I, Michels J, Kratassiouk G, Carmona-Gutierrez D, Scoazec M, Vacchelli E, Schlemmer F, Kepp O, Shen S, Tailler M, Niso-Santano M, Morselli E, Criollo A, Adjemian S, Jemaà M, Chaba K, Pailleret C, Michaud M, Pietrocola F, Tajeddine N, de La Motte Rouge T, Araujo N, Morozova N, Robert T, Ripoche H, Commo F, Besse B, Validire P, Fouret P, Robin A, Dorvault N, Girard P, Gouy S, Pautier P, Jägemann N, Nickel AC, Marsili S, Paccard C, Servant N, Hupé P, Behrens C, Behnam-Motlagh P, Kohno K, Cremer I, Damotte D, Alifano M, Midttun O, Ueland PM, Lazar V, Dessen P, Zischka H, Chatelut E, Castedo M, Madeo F, Barillot E, Thomale J, Wistuba II, Sautès-Fridman C, Zitvogel L, Soria JC, Harel-Bellan A, Kroemer G. Galluzzi L, et al. Among authors: soria jc. Cell Rep. 2012 Aug 30;2(2):257-69. doi: 10.1016/j.celrep.2012.06.017. Epub 2012 Jul 26. Cell Rep. 2012. PMID: 22854025 Free article.
A dose finding, safety and pharmacokinetic study of AVE1642, an anti-insulin-like growth factor-1 receptor (IGF-1R/CD221) monoclonal antibody, administered as a single agent and in combination with docetaxel in patients with advanced solid tumours.
Soria JC, Massard C, Lazar V, Ozoux ML, Mery-Mignard D, Deslandes A, Tolcher AW. Soria JC, et al. Eur J Cancer. 2013 May;49(8):1799-807. doi: 10.1016/j.ejca.2013.01.003. Epub 2013 Feb 26. Eur J Cancer. 2013. PMID: 23485230 Clinical Trial.
Cisplatin resistance associated with PARP hyperactivation.
Michels J, Vitale I, Galluzzi L, Adam J, Olaussen KA, Kepp O, Senovilla L, Talhaoui I, Guegan J, Enot DP, Talbot M, Robin A, Girard P, Oréar C, Lissa D, Sukkurwala AQ, Garcia P, Behnam-Motlagh P, Kohno K, Wu GS, Brenner C, Dessen P, Saparbaev M, Soria JC, Castedo M, Kroemer G. Michels J, et al. Among authors: soria jc. Cancer Res. 2013 Apr 1;73(7):2271-80. doi: 10.1158/0008-5472.CAN-12-3000. Cancer Res. 2013. PMID: 23554447
Sorafenib plus dacarbazine in solid tumors: a phase I study with dynamic contrast-enhanced ultrasonography and genomic analysis of sequential tumor biopsy samples.
Lazar V, Lassau N, Meurice G, Loriot Y, Peña C, Massard C, Robert C, Robert T, Le Berre MA, de Baere T, Dessen P, Soria JC, Armand JP. Lazar V, et al. Among authors: soria jc. Invest New Drugs. 2014 Apr;32(2):312-22. doi: 10.1007/s10637-013-9993-0. Epub 2013 Aug 27. Invest New Drugs. 2014. PMID: 23979492 Clinical Trial.
733 results